Previous 10 | Next 10 |
Delcath Systems Reports First Quarter 2024 Results and Business Highlights PR Newswire Conference Call Today at 8:30 am Eastern Time QUEENSBURY, N.Y. , May 14, 2024 /PRNewswire/ -- Delcath Systems, Inc. (Nasdaq: DCTH) ("Delcath" or the "Company"), an ...
2024-05-13 18:15:04 ET Stephens analyst issues OVERWEIGHT recommendation for DCTH on May 13, 2024 04:20PM ET. DCTH was trading at $5.4 at issue of the analyst recommendation. The overall analyst consensus : BUY. Current analyst recommendations are : 3 - Buy, 1 - Hold rec...
2024-05-13 13:36:00 ET More on Delcath Systems Delcath Systems Inc (DCTH) Q4 2023 Earnings Call Transcript Delcath Systems announces $7 million private placement Seeking Alpha’s Quant Rating on Delcath Systems Historical earnings data for Delcath Syste...
Delcath Systems to Host First Quarter 2024 Earnings Call PR Newswire QUEENSBURY, N.Y. , May 7, 2024 /PRNewswire/ -- Delcath Systems, Inc. (Nasdaq: DCTH), an interventional oncology company focused on the treatment of primary and metastatic cancers of the live...
Publication of Results from Pivotal FOCUS Study in Metastatic Uveal Melanoma Patients treated with HEPZATO KIT PR Newswire Significantly Higher Overall Response Rate vs Meta-analysis of Historical Controls (36.3% vs. 5.5%) Other Efficacy Endpoints Include a 73.6% Disea...
Delcath Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) PR Newswire NEW YORK , April 4, 2024 /PRNewswire/ -- Delcath Systems, Inc. (Nasdaq: DCTH) (the "Company" or "Delcath"), an interventional oncology company focused on the treatment of primary ...
2024-03-27 09:15:03 ET Canaccord Genuity analyst issues BUY recommendation for DCTH on March 27, 2024 08:09AM ET. The previous analyst recommendation was Buy. DCTH was trading at $4.61 at issue of the analyst recommendation. The overall analyst consensus : BUY. Curre...
2024-03-26 12:49:07 ET Delcath Systems Inc (DCTH) Q4 2023 Results Conference Call March 26, 2024 8:30 AM ET Company Participants David Hoffman - General Counsel, Corporate Secretary & Chief Compliance Officer Gerard Michel - CEO & Director Sandra Pennell ...
2024-03-26 07:33:09 ET More on Delcath Systems Delcath Systems announces $7 million private placement Delcath Systems announces CMS established product-specific J-code for HEPZATO Seeking Alpha’s Quant Rating on Delcath Systems Historical earnings data...
Delcath Systems Reports Fourth Quarter and Full Year 2023 Results and Provides Business Update PR Newswire Increases 2024 Treatment Site Activation Guidance to 20 Sites QUEENSBURY, N.Y. , March 26, 2024 /PRNewswire/ -- Delcath Systems, Inc. (Nasdaq: DCTH)...
News, Short Squeeze, Breakout and More Instantly...
Delcath Systems, Inc. (Nasdaq: DCTH), an interventional oncology company focused on the treatment of primary and metastatic cancers of the liver, announced today it will host a conference call on August 5, 2024, at 4:30 PM Eastern Time to discuss results for its second quarter ended June 30, 2024...
2024-07-16 23:20:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
2024-06-17 07:10:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...